CA3191119A1 - Antitumoral ascorbic acid esters - Google Patents
Antitumoral ascorbic acid estersInfo
- Publication number
- CA3191119A1 CA3191119A1 CA3191119A CA3191119A CA3191119A1 CA 3191119 A1 CA3191119 A1 CA 3191119A1 CA 3191119 A CA3191119 A CA 3191119A CA 3191119 A CA3191119 A CA 3191119A CA 3191119 A1 CA3191119 A1 CA 3191119A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- mmol
- ethylacetate
- esi
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/32—Oxygen atoms
- C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/32—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20382804.1A EP3967684A1 (en) | 2020-09-14 | 2020-09-14 | Antitumoral ascorbic acid esters |
| EP20382804.1 | 2020-09-14 | ||
| PCT/EP2021/075104 WO2022053679A1 (en) | 2020-09-14 | 2021-09-13 | Antitumoral ascorbic acid esters |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3191119A1 true CA3191119A1 (en) | 2022-03-17 |
Family
ID=72709280
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3191119A Pending CA3191119A1 (en) | 2020-09-14 | 2021-09-13 | Antitumoral ascorbic acid esters |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230278974A1 (https=) |
| EP (2) | EP3967684A1 (https=) |
| JP (1) | JP7805651B2 (https=) |
| KR (1) | KR20230088718A (https=) |
| CN (1) | CN116724028B (https=) |
| AU (1) | AU2021339010A1 (https=) |
| CA (1) | CA3191119A1 (https=) |
| ES (1) | ES3006988T3 (https=) |
| MX (1) | MX2023002970A (https=) |
| WO (1) | WO2022053679A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4676461A1 (en) * | 2023-03-09 | 2026-01-14 | Mastery Biotech Co., Ltd. | Conjugate compound comprising 13-cis-retinoic acid and ascorbic acid |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2831395B2 (ja) * | 1989-09-12 | 1998-12-02 | ハリマ化成株式会社 | アスコルビン酸エステル |
| JP3781877B2 (ja) * | 1997-10-03 | 2006-05-31 | 株式会社ムック | アスコルビン酸誘導体またはその塩、および医薬 |
| CN101550119B (zh) | 2009-05-11 | 2012-05-30 | 无锡宏瑞生物医药科技有限公司 | 芳基(乙)丙酸抗坏血酸酯,其制备方法及含有它们的药物 |
| JP2016104708A (ja) | 2014-12-01 | 2016-06-09 | 参天製薬株式会社 | アスコルビン酸誘導体を含有する非水性注射剤及びデポ形成方法 |
| JP6588764B2 (ja) | 2015-01-26 | 2019-10-09 | 章博 田井 | 抗腫瘍剤 |
| CN106139151A (zh) * | 2016-04-29 | 2016-11-23 | 陈西敬 | 抗坏血酸棕榈酰酯与抗肿瘤药物协同作用的药物组合物 |
| CA3031979A1 (en) * | 2016-08-01 | 2018-02-08 | IC-MedTech Corp. | Ascorbic acid, quinone compound, and sodium glucose cotransporter inhibitor for treating cancer |
-
2020
- 2020-09-14 EP EP20382804.1A patent/EP3967684A1/en not_active Withdrawn
-
2021
- 2021-09-13 MX MX2023002970A patent/MX2023002970A/es unknown
- 2021-09-13 US US18/043,620 patent/US20230278974A1/en active Pending
- 2021-09-13 JP JP2023515364A patent/JP7805651B2/ja active Active
- 2021-09-13 WO PCT/EP2021/075104 patent/WO2022053679A1/en not_active Ceased
- 2021-09-13 CA CA3191119A patent/CA3191119A1/en active Pending
- 2021-09-13 EP EP21777302.7A patent/EP4211123B1/en active Active
- 2021-09-13 ES ES21777302T patent/ES3006988T3/es active Active
- 2021-09-13 AU AU2021339010A patent/AU2021339010A1/en active Pending
- 2021-09-13 KR KR1020237012737A patent/KR20230088718A/ko active Pending
- 2021-09-13 CN CN202180062720.9A patent/CN116724028B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230088718A (ko) | 2023-06-20 |
| ES3006988T3 (en) | 2025-03-19 |
| JP7805651B2 (ja) | 2026-01-26 |
| EP4211123C0 (en) | 2024-11-06 |
| JP2023541840A (ja) | 2023-10-04 |
| CN116724028B (zh) | 2025-07-08 |
| WO2022053679A1 (en) | 2022-03-17 |
| US20230278974A1 (en) | 2023-09-07 |
| AU2021339010A1 (en) | 2023-03-23 |
| EP4211123A1 (en) | 2023-07-19 |
| CN116724028A (zh) | 2023-09-08 |
| EP4211123B1 (en) | 2024-11-06 |
| EP3967684A1 (en) | 2022-03-16 |
| MX2023002970A (es) | 2023-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6031122B2 (ja) | 抗微生物療法のための三環式ホウ素化合物 | |
| CN112804995A (zh) | 隐杯伞素类似物、其应用及其合成方法 | |
| EP3029043B1 (en) | Tricyclic benzoxaborole compound, preparation method therefor, and use thereof | |
| NZ517069A (en) | New stilbenes with vascular damaging activity | |
| CN104024213A (zh) | 合成的表没食子儿茶素没食子酸酯(egcg)类似物 | |
| EP4211123B1 (en) | Antitumoral ascorbic acid esters | |
| US10494341B2 (en) | Compound containing indoleacetic acid core structure and use thereof | |
| CN103304573B (zh) | 石蒜碱类化合物在制备抗肿瘤药物的应用 | |
| JP5529280B2 (ja) | 癌治療用のジ（フェニルプロパノイド）・グリセロール誘導体 | |
| US9115116B2 (en) | Dual action inhibitors against histone deacetylases and 3-hydroxy-3-methylglutaryl coenzyme a reductase | |
| JP5701387B2 (ja) | ベルバミンのジカルボキシミド誘導体、その調製方法及び使用 | |
| CN114380864A (zh) | 一种双氢青蒿素衍生物、制备方法、药物组合物和其在制备抗肿瘤药物中的应用 | |
| AU2009279400A1 (en) | Lipid compounds for supression of tumorigenesis | |
| WO2025008773A1 (en) | Mitochondria specific transcription inhibitor compounds | |
| US20240101585A1 (en) | Heteroaromatic phosphonium salts and their use treating cancer | |
| AU2024278807A1 (en) | Mitochondria specific transcription inhibitors | |
| WO2010090234A1 (ja) | 12-デオキシフシコクシン糖鎖改変誘導体およびその用途 | |
| HK40070404A (en) | Compound containing an indoleacetic acid core structure and use thereof | |
| JP4389028B2 (ja) | 抗腫瘍剤 | |
| WO2022040788A1 (en) | Open-ring and lactone derivatives of unsaturated trihydroxy c-18 fatty acids and pharmaceutical compositions thereof having anti-cancer activity | |
| CN103450164A (zh) | 格尔德霉素衍生物及其制备方法和用途 | |
| JP2005023048A (ja) | ３−アシル−４−アルキル−５−ヒドロキシメチルテトロン酸誘導体及びこれを有効成分とする医薬 | |
| HK1102562A (en) | Phosphate-bearing prodrugs of sulfonyl hydrazines as hypoxia-selective antineoplastic agents | |
| JP2016190796A (ja) | 抗がん剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240906 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240906 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240906 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250807 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250807 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250905 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250909 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20251008 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20251008 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251008 |